Compare AbbVie Inc (ABBV) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares International Treasury Bond ETF — how do they compare? AbbVie Inc trades at $249.63 (market cap $441.94B), while iShares International Treasury Bond ETF trades at $41.27. The key difference: AbbVie Inc pays a 2.77% dividend while iShares International Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IGOV | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $43.09 |
52-Week Low | $197.38 | $40.35 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
IGOV trades at $41.13, down 0.15% on the day, with a bullish technical signal driven by moving averages despite neutral oscillators. The stock shows consolidated trading near key support at $41. Financial data remains limited, but recent news highlights significant exposure to global bond market volatility through its ETF structure.
The outlook is clouded by interest rate sensitivity and inflationary pressures, posing downside risks. Investment appeal hinges on macroeconomic stability, while the primary opportunity lies in potential yield curve normalization benefiting long-duration assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
